Skip to main content

Search

Reset all filters
828 Result(s)
Sort by

BI Access to Healthcare Strategy_Availability

BI Access to Healthcare Strategy_Availability

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Behind the Lab

Behind the Lab

Delve behind the lab to see how our Retinal Health scientists are spearheading research into novel therapeutics to treat retinopathies.
collaboration criving innovation

collaboration criving innovation

In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.
Collaboration to fight NCDs

Collaboration to fight NCDs

70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.
FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
Collaboration-with-OxfordBioTherapeutics

Collaboration-with-OxfordBioTherapeutics

Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
clinical_collaboration_with_Mirati

clinical_collaboration_with_Mirati

Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.
collaboration-LIBD

collaboration-LIBD

Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
Powered By Our People – A Global IT Community

Powered By Our People – A Global IT Community

With state-of-the-art digital tranformation and almost 2,000 colleagues working in IT at our locations across the world, we have powered the unprecedented growth of our global IT team – the people behind our pioneering information technology progress
global-top-employer

global-top-employer

For the first time, Boehringer Ingelheim receives the award as a Global Top Employer as well as individual awards in 27 countries.
Revolutionizing drug development

Revolutionizing drug development

Our scientists are leveraging the "digital twins"-technology to revolutionize biotherapeutic drug development.
Animal Health Collaboration with Novozymes

Animal Health Collaboration with Novozymes

Boehringer Ingelheim Animal Health and Novozymes today announced a strategic collaboration to develop and commercialize probiotics for global poultry production. Boehringer Ingelheim will market and distribute Novozymes’ FloraMax® probiotic product f